These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments. Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374 [TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376 [TBL] [Abstract][Full Text] [Related]
4. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis. Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789 [TBL] [Abstract][Full Text] [Related]
5. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Shields MD; Chen K; Dutcher G; Patel I; Pellini B Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272 [TBL] [Abstract][Full Text] [Related]
6. Regulatory implications of ctDNA in immuno-oncology for solid tumors. Vellanki PJ; Ghosh S; Pathak A; Fusco MJ; Bloomquist EW; Tang S; Singh H; Philip R; Pazdur R; Beaver JA J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36796877 [TBL] [Abstract][Full Text] [Related]
7. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155 [TBL] [Abstract][Full Text] [Related]
8. Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer. Tian X; Liu X; Wang K; Wang R; Li Y; Qian K; Wang T; Zhao X; Liu L; Zhang PL; Xiong Y; Rui J; Chen R; Zhang Y Thorac Cancer; 2024 Apr; 15(10):797-807. PubMed ID: 38409945 [TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801 [TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. Arisi MF; Dotan E; Fernandez SV Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259 [TBL] [Abstract][Full Text] [Related]
11. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783 [TBL] [Abstract][Full Text] [Related]
12. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872 [TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA: current challenges for clinical utility. Dang DK; Park BH J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection. Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827 [TBL] [Abstract][Full Text] [Related]
15. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach. Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066 [TBL] [Abstract][Full Text] [Related]
16. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer. Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093 [TBL] [Abstract][Full Text] [Related]
18. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868 [No Abstract] [Full Text] [Related]
19. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Qiu B; Guo W; Zhang F; Lv F; Ji Y; Peng Y; Chen X; Bao H; Xu Y; Shao Y; Tan F; Xue Q; Gao S; He J Nat Commun; 2021 Nov; 12(1):6770. PubMed ID: 34799585 [TBL] [Abstract][Full Text] [Related]
20. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]